Biofourmis is a fast-growing global health IT start-up founded in Singapore that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. The company discovers, develops and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis has built Biovitals?, a highly sophisticated personalized artificial intelligence (AI)-powered health analytics platform that predicts clinical exacerbation days in advance before a critical event. Biovitals? is the backbone of the company?s Digital Therapeutics product pipeline, which spans a number of therapeutic areas and disease states, including heart failure, acute coronary syndrome, COPD and chronic pain.

Affectiva, an MIT Media Lab spin-off, is the pioneer in Emotion AI, the next frontier of artificial intelligence. Affectiva's mission is to bring emotional intelligence to the digital world with our emotion recognition technology that senses and analyzes facial expressions and emotion. Our patented software is built on an emotion AI science platform that uses computer vision, deep learning and the world's largest emotion data repository of more than 4.9 million faces analyzed from 75 countries, amounting to more than 50 billion emotion data points. Affectiva's SDKs and APIs enable developers to add emotion-sensing and analytics to their own mobile apps, games, devices, applications and digital experiences. Affectiva is also used by more than 1,400 brands, like Kellogg's, MARS and CBS to gather insight and analytics in consumer emotional engagement.